A large U.S. health records study suggests that difficulty seeing blood in urine may put color-blind patients at higher risk.

Published, peer-reviewed research shows a patent-pending, virus-mimicking platform technology developed at Purdue University ...

People with color vision deficiency -- commonly known as color blindness -- may have a higher risk of mortality from bladder ...

People who are colorblind may be missing a life-saving warning sign of bladder cancer. Analysis of the electronic health ...

The analysis showed a higher long-term mortality risk among bladder cancer patients with color vision deficiency. These findings suggest that impaired color vision may negatively influence outcomes in ...

The American Cancer Society estimates that over 80,000 individuals will be diagnosed with bladder cancer this year.

Dr. Soon-Shiong is hopeful the Saudi Arabian FDA's approval of his cancer therapy drug, Anktiva, will lead to widespread ...

When you learn you have bladder cancer, it’s only natural to ask: "Can I survive this, for how long, and can I expect to be cured?" You may have searched online for survival rate information. These ...

A research team at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) has developed a radiopharmaceutical molecule marker that ...

ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best penny stocks to buy for 2026. On December 16, ImmunityBio, Inc.

What Is Zusduri Used For? Zusduri is used to treat a certain type of recurrent, persistent bladder cancer known as LG-IR-NMIBC. About 75% of people with bladder cancer present with non-muscle invasive ...

ImmunityBio’s IBRX QUILT-2.005 trial tops enrollment forecasts; BLA filing targeted by year-end after positive ANKTIVA+BCG ...